Recall Forensics

Recall Forensics: The RAPTURE Preworkout DMAA Recall — the validation failure behind it

Team ValidLeaf · October 2026 · 6 min read

Recall Forensics is our series tracing real dietary supplement recalls and FDA enforcement actions to the specific validation gap behind them. Every fact comes from public regulator records or trade-press reporting of those records — no speculation, no invented causes. This case is about a pre-workout powder the FDA flagged in May that kept selling until a nationwide recall in October — and the banned stimulant that should never have cleared incoming inspection in the first place.

What happened

On October 6, 2026, Leader Formulas, LLC of Tomball, Texas, announced a nationwide recall of one lot of RAPTURE Preworkout — lot 260327-4 — after FDA laboratory testing found the powder contained 1,3-dimethylamylamine (DMAA), a stimulant the FDA says is not a legal dietary ingredient. The FDA posted the company's announcement the next day, October 7 (USA Today; Medical Daily).

The recall covers three flavors, each sold in a 450-gram round plastic container with red and black lettering and a rhinoceros-print seal: Rainbow Twist (UPC 710154236506), Electric Lemonade (UPC 710143 236513), and Berry Mojito (UPC 710154236544). The affected lot was distributed nationwide through retail stores and the company's own website, leaderformulas.com, from January 29, 2025 through May 25, 2026 — nearly sixteen months on the market. Leader Formulas reported no adverse events as of the announcement (The Healthy; Medical Daily).

What makes this case different is the calendar. On May 5, 2026, the FDA issued a health-fraud notice about RAPTURE Preworkout, saying its lab analysis had found DMAA that was not declared on the label and advising consumers not to buy or use the product. Distribution continued until May 25 — roughly three weeks past that public warning. The recall was evidently initiated on June 25, and the FDA classified it as Class I, its highest risk level, on October 2 — with the public announcement landing on October 6. In other words, five months separate the agency's warning from the recall that followed (The Healthy; Medical Daily).

DMAA is no stranger to the regulator. The FDA sent 18 warning letters over DMAA-containing products between 2012 and 2017, and in 2019 the U.S. Court of Appeals for the Eleventh Circuit upheld the agency's position that DMAA is not a dietary ingredient — a ruling the Supreme Court left standing when it declined review, after which seized DMAA products were destroyed in November 2020. The agency publishes the aliases buyers should watch for: methylhexanamine, geranamine, 1,3-dimethylpentylamine, and label names like "geranium extract" or Pelargonium graveolens extract — and says it is not aware of reliable science showing DMAA occurs naturally in plants (Medical Daily).

An honesty note, because we hold ourselves to it: public reporting does not establish how DMAA entered the product — whether it was a deliberate formula input, a mislabeled raw material from a supplier, or contamination further up the chain. The mechanism has not been publicly detailed, and the June 25 recall-initiation date comes from The Healthy's reading of FDA recall records rather than a date the company published. The lesson below applies regardless of the route it took.

The validation gap: component identity testing that would have made the May warning unnecessary

The striking thing about this timeline is not the recall — it is how many quality gates DMAA passed on the way in. A stimulant the FDA has been chasing for more than a decade, that federal courts have confirmed is not a lawful dietary ingredient, ended up in a finished lot that shipped nationwide for sixteen months. Somewhere in that company's quality system, the question "is every ingredient in this formula confirmed and lawful?" had no working answer.

Under the dietary supplement cGMPs at 21 CFR Part 111, the identity of each component must be confirmed before it goes into a product, and finished products must meet established specifications for identity, purity, strength, and composition. A pre-workout powder is exactly the category where those requirements carry the most weight: performance and energy ingredients are the ones most likely to arrive adulterated, substituted, or spiked. The controls that would have kept DMAA out of the blending room:

• Screen incoming performance ingredients against a banned-substance specification — not just a certificate of analysis. A COA describes what the supplier claims to have shipped. A stimulant-category ingredient that is never independently screened for DMAA and its aliases is an honor-system component in the one category where honor systems fail most often.
• Qualify the ingredient supplier behind the powder, not just the price. Broker-sourced "energy" blends can change hands several times before they reach a blender. An approved-supplier program with audit history and quality agreements is the only way to know whose hands they passed through.
• Gate the master formula on lawful-ingredient status. Before a single batch is made, every input should clear a simple review: is this a lawful dietary ingredient, and where is the evidence? DMAA fails that gate on the FDA's own published page.
• Verify identity per lot, not per relationship. Long-standing suppliers earn trust; components still change. Per-lot identity confirmation is the cGMP control that survives a good relationship.

This angle sits apart from the other tainted-supplement cases we have traced. In our X10 / biQ-FEL teardown, the brand sold finished goods it never made — the gap was identity verification downstream of manufacturing. In the Niwali tejocote teardown, the wrong botanical entered at the ingredient level. Here the maker is the manufacturer of record and the hidden substance is a long-banned stimulant — the gap is component verification upstream of blending, the one place where a May warning never has to happen.

How a GMP Readiness Assessment catches it

This is the component-level failure a GMP Readiness Assessment is built to surface before the FDA's lab report does. Over four weeks, it reviews your supplement operation for:

• Component identity verification — which incoming ingredients get per-lot identity confirmation under 21 CFR 111.75, and which arrive on certificates alone.
• Banned- and adulterated-ingredient screening — whether your stimulant and performance-category inputs are screened against the substances the FDA has ruled unlawful, including DMAA and its aliases.
• Supplier qualification — approved-supplier status, audit history, and quality agreements for the ingredient brokers behind your formulas.
• Formula governance — the lawful-ingredient gate every master formula passes before its first batch is blended.

It closes with a gap assessment, a remediation roadmap, and starter specification and supplier-qualification templates — so the fix starts before the FDA's lab report does.